Data Foundry

Medical device recalls 2017

ETEST OXACILLIN OX 256 US F100 In vitro diagnostic — Class II medical device recall Z-0264-2018

Terminated recall by BioMerieux SA, reported 2017-12-27, distributed nationwide. QC failures (MIC out of range high) for S.aureus ATCC 29213 strain on ETEST OX 256 (OXACILLIN) Foam packaging

Recall numberZ-0264-2018
Product typeMedical device
ClassificationClass II
StatusTerminated
Voluntary or mandatedVoluntary
Recalling firmBioMerieux SA, Marcy L'Etoile, France
Recall initiated2017-04-13
Classified2017-12-19
Reported by FDA2017-12-27
Terminated2020-08-18
DistributedNationwide (US)
Countries outside the USAT, AU, CA, CH, CZ, DE, DZ, EE, EG, ES, FR, GB, GR, HK, HR, HU, IL, IN, IT, JP, KR, KW, LB, MT, MX, NG, NL, PE, PH, QA, SA, SE, SI, TH, TR, ZA
Quantity1,585 units
Pathogensstaphylococcus
Lot numbers1003059010, 1003315830, 1004071250, 1004818860, 1004890400
Model numbers520558

Product

ETEST OXACILLIN OX 256 US F100 In vitro diagnostic, a quantitative technique for determining the antimicrobial susceptibility of bacteria species.

Reason for recall

QC failures (MIC out of range high) for S.aureus ATCC 29213 strain on ETEST OX 256 (OXACILLIN) Foam packaging (Ref. 520558, 520518) reported. The product behavior could lead to False Resistant results.

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/Z-0264-2018. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.